# A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

> **NCT04712097** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 478 (actual)

## Conditions studied

- Relapsed or Refractory Follicular Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab
- **DRUG:** Tociluzumab

## Key facts

- **NCT ID:** NCT04712097
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-27
- **Primary completion:** 2026-06-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 478 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04712097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04712097, "A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04712097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*